Overview

* Alphatec ( ATEC ) Q2 revenue grows 27.5%, beating analysts' expectations, per LSEG data

* Adjusted EBITDA for Q2 beats consensus, reflecting disciplined execution

* Company raises full-year revenue and profitability guidance

Outlook

* Company expects full-year 2025 revenue to grow 21% to $742 mln

* Alphatec ( ATEC ) raises full-year 2025 adjusted EBITDA guidance to $83 mln

* Company projects 2025 surgical revenue of $666 mln

* Alphatec ( ATEC ) anticipates EOS revenue of $76 mln in 2025

Result Drivers

* SURGICAL REVENUE - 29% growth driven by momentum of PTP™ and LTP™ solutions

* SURGEON ADOPTION - 21% increase in new surgeon adoption, indicating future growth potential

* EBITDA MARGIN EXPANSION - Adjusted EBITDA margin expanded by 880 bps YoY through disciplined execution

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $186 mln $178.80

Revenue mln (9

Analysts

)

Q2 Net -$41 mln

Income

Q2 Beat $23 mln $17.80

Adjusted mln (8

EBITDA Analysts

)

Q2 Gross 70.0%

Margin

Q2 70.0%

Adjusted

Gross

Margin

Q2 Basic -$0.27

EPS

Q2 -$13.08

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for Alphatec Holdings Inc ( ATEC ) is $20.00, about 46.3% above its July 30 closing price of $10.73

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)